神经妥乐平治疗下腰痛的药物经济学评价研究  

Pharmacoeconomic Evaluation on Neurotropin Therapy to Low Back Pain

作　　者：刘克军[1] 

机构地区：[1]卫生部卫生经济研究所,北京100191

出　　处：《中国卫生经济》2010年第7期94-97,共4页Chinese Health Economics

基　　金：卫生部卫生经济研究所药物经济学评价项目的子课题

摘　　要：目的:探讨神经妥乐平针剂和恩再适针剂在下腰痛治疗中的有效性和经济性。方法:142例下腰痛患者的临床多中心、随机、开放和平行对照试验研究和药物经济学费用效果分析。结果:(1)两组VAS疼痛总有效率在第7、14、21和28天时分别为:NSP组52.10%、87.30%、95.80%和97.20%,AGC组37.10%、73.50%、77.60%和84.60%。第7天2组差别无统计学意义,但第14、21和28天2组差别有统计学意义。(2)与恩再适针剂相比,神经妥乐平针剂每例患者1个疗程(14天)可节省直接医疗费用296.00元,每有效治疗1例患者可节省直接医疗费用642.23元。结论:在日剂量和疗程相同的情况下,神经妥乐平针剂治疗下腰痛比恩再适针剂更具有费用效果。Objectives： To explore the validity and economical efficiency of neurotropin and analgecine therapy to low back pain. Methods： Based on an muhieenter randomized control clinical trial of 142 patients, the study uses the method and theory of pharmacoeconomics to make an analysis. Results： （1） Applying the VAS measurement method, the effective rates on the seventh day, the fourteenth day, the twenty-first day and the twenty-eighth day of both groups are 52.10%, 87.30%, 95.80% and 97.20% in NSP group and 37.10%, 73.50%, 77.60% and 84.60% in AGC group separately. Except the effective rate at the seventh day, the differences of the effective rate at the fourteenth day, the twenty-first day and the twenty-eighth day between the two groups has statistical significance. （2） Compared with AGC, 296.00 RMB per patient can be saved in a course of treatment （14 days） using NSP. And if the index of per patient whose treatment is effective is considered, the saved money will increase to 642.23 RMB. Conclusion： In the case of the same therapy course and the dosage per day, neurotropin has more cost effectiveness than analgecine at treating low back pain.

关 键 词：费用效果分析 随机对照临床试验 神经妥乐平 恩再适 

分 类 号：R681.5[医药卫生—骨科学]